UM

Browse/Search Results:  1-10 of 34 Help

Selected(0)Clear Items/Page:    Sort:
ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials Journal article
Journal of Psychiatric Research, 2018,Volume: 105,Page: 23-32
Authors:  Wang G.;  Zheng W.;  Li X.-B.;  Wang S.-B.;  Cai D.-B.;  Yang X.-H.;  Ungvari G.S.;  Xiang Y.-T.;  Correll C.U.
Favorite  |  View/Download:1/0  |  Submit date:2018/12/18
Clozapine  ECT  Headache  Memory  Remission  Response  Schizophrenia  Treatment-resistant  
Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia 比较奥氮平与其他二代抗精神病药物对改善精神分裂症患者自知力和药物中断率的影响 Journal article
Shanghai Archives of Psychiatry, 2018,Volume: 30,Issue: 3,Page: 178-187
Authors:  He H.;  Zhou Y.;  Yang M.;  Li X.;  Xiang Y.-T.;  Luo J.
Favorite  |  View/Download:0/0  |  Submit date:2018/12/18
Insight  Medication discontinuation rate  Olanzapine  Schizophrenia  Second-generation antipsychotics  
The Atypical Antipsychotic Agent, Clozapine, Protects Against Corticosterone-Induced Death of PC12 Cells by Regulating the Akt/FoxO3a Signaling Pathway Journal article
MOLECULAR NEUROBIOLOGY, 2017,Volume: 54,Issue: 5,Page: 3395-3406
Authors:  Zeng, Zhiwen;  Wang, Xue;  Bhardwaj, Sanjeev K.;  Zhou, Xuanhe;  Little, Peter J.;  Quirion, Remi;  Srivastava, Lalit K.;  Zheng, Wenhua
Favorite  |  View/Download:9/0  |  Submit date:2018/10/30
Schizophrenia  Clozapine  Corticosterone  Pi3k/akt/foxo3a  Neuroprotection  
Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: A meta-analysis of randomized controlled trials Journal article
Journal of Clinical Psychiatry, 2017,Volume: 78,Issue: 5,Page: e498-e505
Authors:  Zheng W.;  Xiang Y.-T.;  Yang X.-H.;  Xiang Y.-Q.;  De Leon J.
Favorite  |  View/Download:8/0  |  Submit date:2018/12/18
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis Journal article
WORLD PSYCHIATRY, 2017,Volume: 16,Issue: 1,Page: 77-89
Authors:  Galling, Britta;  Roldan, Alexandra;  Hagi, Katsuhiko;  Rietschel, Liz;  Walyzada, Frozan;  Zheng, Wei;  Cao, Xiao-Lan;  Xiang, Yu-Tao;  Zink, Mathias;  Kane, John M.;  Nielsen, Jimmi;  Leucht, Stefan;  Correll, Christoph U.
Favorite  |  View/Download:10/0  |  Submit date:2018/10/30
Antipsychotics  Polypharmacy  Augmentation  Monotherapy  Schizophrenia  Clozapine  Aripiprazole  
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients Journal article
Comprehensive Psychiatry, 2016,Volume: 71,Page: 71-76
Authors:  An F.-R.;  Yang R.;  Wang Z.-M.;  Ungvari G.S.;  Ng C.H.;  Chiu H.F.K.;  Wu P.-P.;  Jin X.;  Li L.;  Lok G.K.I.;  Xiang Y.-T.
Favorite  |  View/Download:2/0  |  Submit date:2018/12/18
Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials Journal article
Acta Psychiatrica Scandinavica, 2016,Volume: 134,Issue: 5,Page: 385-398
Authors:  Zheng W.;  Xiang Y.-T.;  Xiang Y.-Q.;  Li X.-B.;  Ungvari G.S.;  Chiu H.F.K.;  Correll C.U.
Favorite  |  View/Download:2/0  |  Submit date:2018/12/18
Antipsychotic  Meta-analysis  Metabolic Abnormalities  Topiramate  Weight Gain  
Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: Meta-analysis of randomized controlled trials Journal article
PLoS ONE, 2016,Volume: 11,Issue: 6
Authors:  Zheng W.;  Cao X.-L.;  Ungvari G.S.;  Xiang Y.-Q.;  Guo T.;  Liu Z.-R.;  Wang Y.-Y.;  Forester B.P.;  Seiner S.J.;  Xiang Y.-T.
Favorite  |  View/Download:2/0  |  Submit date:2018/12/18
Worldwide Differences in Regulations of Clozapine Use Journal article
CNS Drugs, 2016,Volume: 30,Issue: 2,Page: 149–161
Authors:  Jimmi Nielsen;  Corina Young;  Petru Iften;  Taishiro Kishimoto;  Yu-Tao Xiang;  Peter F. J. Schulte;  Christoph U. Correll;  David Taylor
Favorite  |  View/Download:4/0  |  Submit date:2019/01/07
Clozapine  Myocarditis  Absolute Neutrophil Count  Schizoaffective Disorder  Agranulocytosis  
Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China Journal article
International Journal of Clinical Pharmacology and Therapeutics, 2016,Volume: 54,Issue: 1,Page: 36-42
Authors:  Hou C.-L.;  Ma X.-R.;  Zang Y.;  Jia F.-J.;  Lin Y.-Q.;  Chiu H.F.K.;  Ungvari G.S.;  Ng C.H.;  Zhong B.-L.;  Cao X.-L.;  Li Y.;  Cai M.-Y.;  Xiang Y.-T.
Favorite  |  View/Download:2/0  |  Submit date:2018/12/18
Antipsychotic Polypharmacy  China  Community-dwelling  Schizophrenia